Market Overview

UPDATE: Egalet's Egalet-002 Was Well Tolerated, Phase 3 Trial Remains On Track For Completion By Year-End


This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: Biotech News General


Related Articles (EGLT)

An (Almost) Bear-Free Zone: Wall Street Reacts To Cisco's Earnings

Wait For A Short-Term Pullback In Bitcoin